Supernus Pharmaceuticals, Inc. - Common Stock — Bilan (NASDAQ:SUPN) | MetaTrader

Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques

Trimestriel Annuel

Total de l'actif 1.5 B1.69 B1.7 B1.28 B1.37 B1.45 B Total du passif 759.24 M873.3 M816.3 M356.16 M332.34 M390.93 M Total des capitaux propres 744.86 M815.85 M886.2 M921.52 M1.04 B1.06 B Total du passif et des capitaux propres 1.5 B1.69 B1.7 B1.28 B1.37 B1.45 B Dette totale 365.51 M379.25 M401.97 M——— Dette nette -57.02 M39.57 M-59.37 M———

Nouvelles

Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD?

Supernus Pharmaceuticals versera 33,4 millions $ aux détenteurs de CVR

Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript

Supernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates

Bausch Health (BHC) Lags Q1 Earnings Estimates

Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs

Biogen Walloped Wall Street's First Quarter Views; Here's What Happened

BofA réduit l’objectif de cours de Supernus Pharmaceuticals en raison des coûts

Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?

Jefferies réitère sa recommandation d’achat sur Supernus Pharmaceuticals